| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Oxyimperatorin targets multiple pathways involved in inflammation and oxidative stress. As a furanocoumarin, it may exert its anti-inflammatory effects through modulation of inflammatory mediators and signaling pathways. Its antioxidant activity suggests interactions with reactive oxygen species and cellular antioxidant defense systems. The compound's potential anticancer activity indicates effects on cancer cell proliferation and survival. Its furanocoumarin structure is characteristic of compounds with diverse biological activities. However, detailed target information for Oxyimperatorin specifically is limited in the available literature.
|
|---|---|
| ln Vitro |
In vitro, Oxyimperatorin has been studied for its anti-inflammatory and antioxidant activities.【22†8】 As a furanocoumarin, it is expected to exhibit biological activities similar to other members of this class, including modulation of inflammatory mediators and free radical scavenging. Its potential anticancer activity has been suggested.【22†8】 However, detailed in vitro activity data for Oxyimperatorin specifically are limited in the available literature. Researchers often refer to studies on related furanocoumarins such as imperatorin for comparative purposes. The compound's activities are typically assessed using standard cell-free and cell-based assays.
|
| ln Vivo |
In vivo studies of Oxyimperatorin are not extensively documented. As a compound with anti-inflammatory, antioxidant, and potential anticancer activities, it may have potential for studying various disease models. However, comprehensive in vivo efficacy and safety data are limited. The compound is primarily used in phytochemical and pharmacological research. Further studies are needed to fully characterize its in vivo biological activity and therapeutic potential. The compound is intended for research use only and not for human therapeutic applications.
|
| Enzyme Assay |
For in vitro biochemical assays, Oxyimperatorin is evaluated for its antioxidant and anti-inflammatory activities. Antioxidant activity is measured using DPPH, ABTS, or FRAP assays. Anti-inflammatory activity is assessed by measuring inhibition of pro-inflammatory mediators such as COX-2, iNOS, or cytokines using enzyme activity assays or ELISA. Enzyme inhibition studies can be performed to evaluate effects on specific targets. These cell-free and cell-based assays help characterize the compound's biological activities and mechanism of action.
|
| Cell Assay |
In vitro cellular assays for Oxyimperatorin are performed using various cell types including immune cells, cancer cells, and normal cells. Cells are cultured in standard media and treated with the compound at various concentrations. Anti-inflammatory activity is assessed by measuring cytokine production in LPS-stimulated immune cells. Antioxidant activity is assessed by measuring ROS levels using fluorescent probes. Anticancer activity is assessed using cell viability, proliferation, and apoptosis assays. These cellular assays help validate the compound's anti-inflammatory, antioxidant, and potential anticancer activities.
|
| Animal Protocol |
In vivo animal experiments with Oxyimperatorin are not extensively documented. As a compound with anti-inflammatory and antioxidant activities, it could be studied in models of inflammation and oxidative stress-related diseases. Administration routes would include oral gavage, intraperitoneal injection, or intravenous injection. Efficacy endpoints would depend on the specific disease model and could include inflammation markers, oxidative stress markers, or disease severity. Researchers should consult the primary literature for any available in vivo protocols and data.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Oxyimperatorin are not extensively documented. As a furanocoumarin with a molecular weight of 286.28, it is expected to have moderate oral bioavailability and good tissue distribution. The compound is soluble in organic solvents. Detailed PK parameters such as half-life, Cmax, Tmax, AUC, and protein binding are not available in the literature. The compound should be stored at -20°C. Researchers should consult the primary literature for any available pharmacokinetic data.
|
| Toxicity/Toxicokinetics |
The toxicological profile of Oxyimperatorin is not extensively characterized. As a natural furanocoumarin, it may have dose-dependent toxicity at high concentrations. Furanocoumarins are known to have phototoxic potential, and appropriate precautions should be taken when handling the compound. The compound is intended for research use only and not for human therapeutic applications. Comprehensive toxicity studies including acute, subchronic, and chronic toxicity assessments are limited. Researchers should follow standard laboratory safety practices when handling Oxyimperatorin, including protection from light exposure.
|
| Additional Infomation |
Oxyimperatorin has been reported in asafoetida, asafoetida and angelica dahurica, and available data are available.
Oxyimperatorin is a valuable research tool for studying furanocoumarin pharmacology, particularly in the context of anti-inflammatory and antioxidant activities.【22†8】 Its presence in Angelica species makes it relevant for natural product chemistry and ethnopharmacology research.【22†21】 The compound can be employed to study structure-activity relationships in furanocoumarins and to investigate the mechanisms of anti-inflammatory and antioxidant actions. Its potential anticancer activity provides opportunities for cancer research. Oxyimperatorin is also used as an analytical standard for the quality control of herbal medicines containing furanocoumarins.【22†21-L22】 |
| Molecular Formula |
C16H14O5
|
|---|---|
| Molecular Weight |
286.2794
|
| Exact Mass |
286.084
|
| CAS # |
35740-18-2
|
| PubChem CID |
182251
|
| Appearance |
White to off-white solid
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
471.4±45.0 °C at 760 mmHg
|
| Flash Point |
238.9±28.7 °C
|
| Vapour Pressure |
0.0±1.2 mmHg at 25°C
|
| Index of Refraction |
1.606
|
| LogP |
1.67
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
21
|
| Complexity |
471
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C([H])(C([H])([H])OC2=C3C(C([H])=C([H])C(=O)O3)=C([H])C3C([H])=C([H])OC2=3)C1(C([H])([H])[H])C([H])([H])[H]
|
| InChi Key |
CTJZWFCPUDPLME-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H14O5/c1-16(2)11(21-16)8-19-15-13-10(5-6-18-13)7-9-3-4-12(17)20-14(9)15/h3-7,11H,8H2,1-2H3
|
| Chemical Name |
9-[(3,3-dimethyloxiran-2-yl)methoxy]furo[3,2-g]chromen-7-one
|
| Synonyms |
(±)-Heraclenin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~349.31 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.73 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.73 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.73 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4931 mL | 17.4654 mL | 34.9308 mL | |
| 5 mM | 0.6986 mL | 3.4931 mL | 6.9862 mL | |
| 10 mM | 0.3493 mL | 1.7465 mL | 3.4931 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
